Damien Mcdevitt News Today

/PRNewswire/ -- This week, Aspen Neuroscience will present to the Parkinsons community at the Future of Parkinsons Disease conference, held November 30 –...

The FDA has granted Fast Track designation to ANPD001 to improve motor function in patients with Parkinson disease.

Aspen Neuroscience in Torrey Pines has announced a digital partnership with Emerald Innovations and Rune Labs on a study to treat Parkinson's disease.

/PRNewswire/ -- Aspen Neuroscience today announced that it is partnering with Emerald Innovations, a pioneer in the creation of "invisible" off-body sensors...

/PRNewswire/ -- Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application,...

Sam Altman is best known as the CEO of OpenAI, the artificial intelligence research organisation that developed and launched ChatGPT, currently the

Scientists are reverse-engineering patients’ own skin or blood cells to behave similarly to embryonic cells and using them in tests to treat incurable diseases

Biotech has developed process the uses a patient's own cells for personalized treatment,

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Aspen Neurosciences is developing a cell therapy that uses a patient’s own stem cells to develop a personalized treatment for Parkinson’s disease. The approach is slightly different than that of Bayer, whose experimental Parkinson’s cell therapy is made from stem cells sourced from healthy donors.